Key facts
- This page summarizes Thomas A. Fitzgerald's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2023, 16:39.
Thomas A. Fitzgerald - 28 Sep 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Chief Financial Officer, Director
- Issuer ticker
- RNAZ
- Reported as of
- 28 Sep 2023
- Net transaction value
- +$25,168
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2023, 16:39:08 UTC
- Prior SEC filing
- 19 May 2023
- Next SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas A. Fitzgerald filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 02 Oct 2023.
Change
- Previous filing in this sequence was filed on 19 May 2023.
- Current net transaction value: +$25,168.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAZ
transaction
Common Stock
Purchase
- Transaction value
- $25,168
- Shares
- +49,350
- Change %
- +708%
- Price
- $0.5100
- Shares after
- 56,318
- Date
- 28 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer.
Footnote F2
Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023.